Table 3.

Association of changes in metabolite clusters with changes in log NT-proBNP, KCCQ-OSS, and KCCQ-CSS

Changes in factor	Factor description	log NT-proBNP		KCCQ-OSS		KCCQ-CSS
		Nominal P value	FDR corrected P value	Nominal P value	FDR corrected P value	Nominal P value	FDR corrected P value
Factor 1	Medium-chain acylcarnitines	0.18	0.38	0.11	0.25	0.10	0.21
Factor 2	Branched-chain and aromatic amino acids	0.31	0.51	0.003	0.01	0.004	0.02
Factor 3	Long-chain acylcarnitines	0.01	0.06	<0.001	<0.001	<0.001	<0.001
Factor 4	Long-chain dicarboxyl acylcarnitines	<0.001	<0.001	0.001	0.01	<0.001	<0.001
Factor 5	Miscellaneous amino acids	0.40	0.58	0.71	0.71	0.75	0.75
Factor 6	Ketone-related metabolites and short-chain acylcarnitines	0.08	0.25	0.14	0.26	0.33	0.48
Factor 7	Medium-chain acylcarnitines	0.53	0.63	0.49	0.57	0.07	0.21
Factor 8	Miscellaneous amino acids	0.12	0.32	0.48	0.57	0.49	0.58
Factor 9	Long-chain acylcarnitines	0.53	0.63	0.08	0.25	0.10	0.21
Factor 10	Miscellaneous amino acids	0.002	0.01	0.57	0.62	0.24	0.40
Factor 11	Branched-chain amino acids and short-chain acylcarnitines	0.31	0.51	0.11	0.25	0.19	0.35
Factor 12	Miscellaneous amino acids	0.63	0.68	0.45	0.57	0.56	0.60
Factor 13	Short-chain dicarboxyl acylcarnitines	0.92	0.92	0.48	0.57	0.43	0.56

Model adjusted for baseline factor level, baseline value of the respective outcome, age, race/ethnicity, sex, eGFR, and type 2 diabetes mellitus.

FDR corrected p-values <0.10 were considered statistically significant.

eGFR, estimated glomerular filtration rate; FDR, false discovery rate; KCCQ, Kansas City Cardiomyopathy Questionnaire; CSS, clinical summary score; OSS, overall summary score; NT-proBNP, N-terminal pro B-type natriuretic peptide.